
Michael D. Burkhart
Examiner (ID: 9773, Phone: (571)272-2915 , Office: P/1633 )
| Most Active Art Unit | 1633 |
| Art Unit(s) | 1636, 1633, 1638 |
| Total Applications | 1155 |
| Issued Applications | 604 |
| Pending Applications | 125 |
| Abandoned Applications | 446 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20143973
[patent_doc_number] => 12378300
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-05
[patent_title] => Elimination of CD19-positive lymphoid malignancies by CD19-car expressing NK cells
[patent_app_type] => utility
[patent_app_number] => 16/934606
[patent_app_country] => US
[patent_app_date] => 2020-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 17
[patent_no_of_words] => 12004
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16934606
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/934606 | Elimination of CD19-positive lymphoid malignancies by CD19-car expressing NK cells | Jul 20, 2020 | Issued |
Array
(
[id] => 19521331
[patent_doc_number] => 12123043
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-22
[patent_title] => Methods and means for the production of Ig-like molecules
[patent_app_type] => utility
[patent_app_number] => 16/934925
[patent_app_country] => US
[patent_app_date] => 2020-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 39
[patent_figures_cnt] => 57
[patent_no_of_words] => 32080
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16934925
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/934925 | Methods and means for the production of Ig-like molecules | Jul 20, 2020 | Issued |
Array
(
[id] => 16727842
[patent_doc_number] => 20210094989
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-01
[patent_title] => Silk Proteins
[patent_app_type] => utility
[patent_app_number] => 16/931710
[patent_app_country] => US
[patent_app_date] => 2020-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25699
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16931710
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/931710 | Silk Proteins | Jul 16, 2020 | Abandoned |
Array
(
[id] => 16483963
[patent_doc_number] => 20200377564
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-03
[patent_title] => REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS
[patent_app_type] => utility
[patent_app_number] => 16/875591
[patent_app_country] => US
[patent_app_date] => 2020-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 78916
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16875591
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/875591 | Regulated synthetic gene expression systems | May 14, 2020 | Issued |
Array
(
[id] => 16541314
[patent_doc_number] => 20200407727
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-31
[patent_title] => GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT
[patent_app_type] => utility
[patent_app_number] => 16/858512
[patent_app_country] => US
[patent_app_date] => 2020-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26907
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16858512
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/858512 | Genome editing using effector oligonucleotides for therapeutic treatment | Apr 23, 2020 | Issued |
Array
(
[id] => 17541022
[patent_doc_number] => 11306133
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-19
[patent_title] => Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/858183
[patent_app_country] => US
[patent_app_date] => 2020-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 45
[patent_figures_cnt] => 46
[patent_no_of_words] => 30481
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16858183
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/858183 | Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof | Apr 23, 2020 | Issued |
Array
(
[id] => 17734711
[patent_doc_number] => 20220220170
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => AAV CAPSID CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/605615
[patent_app_country] => US
[patent_app_date] => 2020-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27146
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -37
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605615
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/605615 | AAV CAPSID CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | Apr 22, 2020 | Pending |
Array
(
[id] => 18398114
[patent_doc_number] => 11660229
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-30
[patent_title] => Cancer treatment methods using thermotherapy and/or enhanced immunotherapy
[patent_app_type] => utility
[patent_app_number] => 16/843831
[patent_app_country] => US
[patent_app_date] => 2020-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 67100
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 203
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16843831
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/843831 | Cancer treatment methods using thermotherapy and/or enhanced immunotherapy | Apr 7, 2020 | Issued |
Array
(
[id] => 16711893
[patent_doc_number] => 20210079040
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-18
[patent_title] => METHODS AND COMPOSITIONS FOR TREATMENT OF CARTILAGE AND DISC TISSUE PATHOLOGIES
[patent_app_type] => utility
[patent_app_number] => 16/841276
[patent_app_country] => US
[patent_app_date] => 2020-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27457
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841276
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/841276 | METHODS AND COMPOSITIONS FOR TREATMENT OF CARTILAGE AND DISC TISSUE PATHOLOGIES | Apr 5, 2020 | Abandoned |
Array
(
[id] => 16326812
[patent_doc_number] => 20200297777
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-24
[patent_title] => METHODS OF TRANSDIFFERENTIATION AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/836967
[patent_app_country] => US
[patent_app_date] => 2020-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36058
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 152
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16836967
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/836967 | Methods of transdifferentiation and methods of use thereof | Mar 31, 2020 | Issued |
Array
(
[id] => 16345126
[patent_doc_number] => 20200309776
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => HLA G-MODIFIED CELLS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 16/832321
[patent_app_country] => US
[patent_app_date] => 2020-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15438
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16832321
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/832321 | HLA G-MODIFIED CELLS AND METHODS | Mar 26, 2020 | Abandoned |
Array
(
[id] => 17748303
[patent_doc_number] => 20220226506
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => EXPRESSION CONSTRUCTS FOR THE GENETIC MODIFICATION OF CELLS
[patent_app_type] => utility
[patent_app_number] => 17/439921
[patent_app_country] => US
[patent_app_date] => 2020-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14361
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17439921
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/439921 | EXPRESSION CONSTRUCTS FOR THE GENETIC MODIFICATION OF CELLS | Mar 16, 2020 | Pending |
Array
(
[id] => 17664111
[patent_doc_number] => 11357787
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-06-14
[patent_title] => Method for selecting cells, method for producing nucleic acid, method for producing recombinant cells, method for producing target substance, method for producing pharmaceutical composition, and reagent
[patent_app_type] => utility
[patent_app_number] => 17/431268
[patent_app_country] => US
[patent_app_date] => 2020-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 10
[patent_no_of_words] => 13877
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 229
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17431268
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/431268 | Method for selecting cells, method for producing nucleic acid, method for producing recombinant cells, method for producing target substance, method for producing pharmaceutical composition, and reagent | Feb 16, 2020 | Issued |
Array
(
[id] => 16013453
[patent_doc_number] => 20200181569
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => EXPANDABLE CELL POPULATIONS FROM BRAIN BIOPSIES OF LIVING SUBJECTS
[patent_app_type] => utility
[patent_app_number] => 16/788037
[patent_app_country] => US
[patent_app_date] => 2020-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11342
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16788037
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/788037 | EXPANDABLE CELL POPULATIONS FROM BRAIN BIOPSIES OF LIVING SUBJECTS | Feb 10, 2020 | Abandoned |
Array
(
[id] => 16188561
[patent_doc_number] => 20200229410
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-23
[patent_title] => GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/782708
[patent_app_country] => US
[patent_app_date] => 2020-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37875
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16782708
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/782708 | Genetically modified non-human animals and methods of use thereof | Feb 4, 2020 | Issued |
Array
(
[id] => 16590580
[patent_doc_number] => 10899830
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-01-26
[patent_title] => Methods and compositions for delivering MRNA coded antibodies
[patent_app_type] => utility
[patent_app_number] => 16/752327
[patent_app_country] => US
[patent_app_date] => 2020-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 17916
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16752327
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/752327 | Methods and compositions for delivering MRNA coded antibodies | Jan 23, 2020 | Issued |
Array
(
[id] => 18301092
[patent_doc_number] => 11622978
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-11
[patent_title] => Immune cells defective for SUV39H1
[patent_app_type] => utility
[patent_app_number] => 16/747198
[patent_app_country] => US
[patent_app_date] => 2020-01-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 18708
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16747198
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/747198 | Immune cells defective for SUV39H1 | Jan 19, 2020 | Issued |
Array
(
[id] => 15899205
[patent_doc_number] => 20200149121
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-14
[patent_title] => METHOD FOR UTILIZING ENGINEERED DENDRITIC CELLS TO INDUCE GUT-HOMING REGULATORY T CELLS AND TREAT GUT INFLAMMATION
[patent_app_type] => utility
[patent_app_number] => 16/744296
[patent_app_country] => US
[patent_app_date] => 2020-01-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16831
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16744296
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/744296 | Method for utilizing engineered dendritic cells to induce gut-homing regulatory T cells and treat gut inflammation | Jan 15, 2020 | Issued |
Array
(
[id] => 17312862
[patent_doc_number] => 20210401910
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => EXPRESSION VECTOR, PHARMACEUTICAL COMPOSITION AND METHOD FOR PREPARING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/733453
[patent_app_country] => US
[patent_app_date] => 2020-01-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5419
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16733453
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/733453 | EXPRESSION VECTOR, PHARMACEUTICAL COMPOSITION AND METHOD FOR PREPARING THE SAME | Jan 2, 2020 | Abandoned |
Array
(
[id] => 16748866
[patent_doc_number] => 20210100875
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-08
[patent_title] => RESTORATION OF VISUAL RESPONSES BY IN VIVO DELIVERY OF RHODOPSIN NUCLEIC ACIDS
[patent_app_type] => utility
[patent_app_number] => 16/700201
[patent_app_country] => US
[patent_app_date] => 2019-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22778
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700201
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/700201 | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids | Dec 1, 2019 | Issued |